Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1910 1
1911 1
1912 2
1916 5
1917 1
1919 5
1920 1
1921 2
1922 1
1924 3
1925 2
1926 1
1927 1
1928 3
1929 1
1931 1
1932 4
1933 1
1934 2
1936 1
1937 2
1938 15
1939 12
1940 21
1941 24
1942 14
1943 13
1944 12
1945 197
1946 723
1947 792
1948 926
1949 676
1950 1092
1951 1582
1952 1642
1953 1812
1954 1783
1955 1690
1956 1517
1957 1654
1958 1486
1959 1548
1960 1527
1961 1823
1962 1919
1963 2793
1964 9383
1965 12869
1966 13023
1967 16120
1968 18785
1969 20356
1970 21139
1971 22811
1972 23528
1973 24914
1974 25353
1975 23232
1976 22452
1977 23106
1978 23769
1979 25664
1980 25449
1981 26086
1982 28912
1983 30269
1984 32561
1985 34344
1986 35723
1987 36348
1988 38642
1989 42481
1990 45804
1991 45581
1992 46328
1993 47625
1994 48498
1995 50458
1996 52465
1997 54423
1998 58230
1999 60885
2000 65269
2001 68522
2002 74793
2003 82374
2004 86178
2005 93662
2006 100337
2007 105399
2008 111465
2009 116287
2010 126112
2011 135107
2012 142603
2013 148494
2014 154436
2015 158493
2016 158067
2017 159741
2018 161821
2019 164481
2020 151258
2021 51808
2022 1
Text availability
Article attribute
Article type
Publication date

Search Results

3,534,351 results
Results by year
Filters applied: . Clear all
Page 1
[Chemotherapy].
Fujita S, Kotake K. Fujita S, et al. Nihon Rinsho. 2014 Jan;72(1):102-7. Nihon Rinsho. 2014. PMID: 24597356 Review. Japanese.
Treatments should be tailored to an individual patient according to tumor characteristics and patient conditions. Conversion therapy is secondary surgery after most active induction chemotherapy, e.g., FOLFOX with cetuximab. Conversion rate is about 10%. Adjuvant …
Treatments should be tailored to an individual patient according to tumor characteristics and patient conditions. Conversion therapy
[Hyperthermic intraperitoneal chemotherapy].
Leebmann H, Piso P. Leebmann H, et al. Chirurg. 2019 Jul;90(7):593-604. doi: 10.1007/s00104-019-0982-5. Chirurg. 2019. PMID: 31190081 Review. German.
Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) are recognized as the standard of care for selected patients with peritoneal malignancies. A complete macroscopic cytoreduction is the basis for a successful multimodal treatment. The signifi …
Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) are recognized as the standard of care for selected …
Enteral tube administration of oral chemotherapy drugs.
Spencer SH, Menard SM, Labedz MZ, Krueger CD, Sarna KV. Spencer SH, et al. J Oncol Pharm Pract. 2020 Apr;26(3):703-717. doi: 10.1177/1078155219893449. Epub 2020 Jan 19. J Oncol Pharm Pract. 2020. PMID: 31955701 Review.
The purpose of this review is to compile available data that describe enteral tube administration of oral chemotherapy agents. Data sources: A systematic evaluation of all Food and Drug Administration-approved oral chemotherapy agents through 31 July 2019 was …
The purpose of this review is to compile available data that describe enteral tube administration of oral chemotherapy agents. Data s …
Chemotherapy is getting 'smarter'.
Mehrling T. Mehrling T. Future Oncol. 2015;11(4):549-52. doi: 10.2217/fon.14.248. Future Oncol. 2015. PMID: 25686110 No abstract available.
[Chemotherapy cancer treatment during the past sixty years].
Furue H. Furue H. Gan To Kagaku Ryoho. 2003 Oct;30(10):1404-11. Gan To Kagaku Ryoho. 2003. PMID: 14584272 Review. Japanese.
Although history of cancer chemotherapy is relatively short, its role is expanding. Cancer chemotherapy provides variably effective treatment for the majority of human cancer and curative treatment for some categories of cancer. ...This progress has resulted from ma …
Although history of cancer chemotherapy is relatively short, its role is expanding. Cancer chemotherapy provides variably effe …
Danger signals: Chemotherapy enhancers?
Rivera Vargas T, Apetoh L. Rivera Vargas T, et al. Immunol Rev. 2017 Nov;280(1):175-193. doi: 10.1111/imr.12581. Immunol Rev. 2017. PMID: 29027217 Review.
We and others have shown that dying tumor cells treated with some chemotherapies are able to induce anticancer immune responses, which rely on their release of danger signals such as the nuclear protein HMGB1. DNA can also be released from chemotherapy-treated tumor …
We and others have shown that dying tumor cells treated with some chemotherapies are able to induce anticancer immune responses, whic …
Alteration of DNA Methylation in Gastric Cancer with Chemotherapy.
Choi SJ, Jung SW, Huh S, Chung YS, Cho H, Kang H. Choi SJ, et al. J Microbiol Biotechnol. 2017 Aug 28;27(8):1367-1378. doi: 10.4014/jmb.1704.04035. J Microbiol Biotechnol. 2017. PMID: 28621113 Free article. Review.
These changes in DNA methylation status could be used as biomarkers for the diagnosis and prognosis of cancer patients undergoing chemotherapies or other clinical therapies. Herein, we describe genes for which methylation is dependent upon anticancer drug resistance …
These changes in DNA methylation status could be used as biomarkers for the diagnosis and prognosis of cancer patients undergoing chemoth
Risk factors for febrile neutropenia among patients with cancer receiving chemotherapy: A systematic review.
Lyman GH, Abella E, Pettengell R. Lyman GH, et al. Crit Rev Oncol Hematol. 2014 Jun;90(3):190-9. doi: 10.1016/j.critrevonc.2013.12.006. Epub 2013 Dec 12. Crit Rev Oncol Hematol. 2014. PMID: 24434034 Review.
Neutropenia with fever (febrile neutropenia [FN]) is a serious consequence of myelosuppressive chemotherapy that usually results in hospitalization and the need for intravenous antibiotics. FN may result in dose reductions, delays, or even discontinuation of chemotherap
Neutropenia with fever (febrile neutropenia [FN]) is a serious consequence of myelosuppressive chemotherapy that usually results in h …
Chemotherapy and Beyond: Infections in the Era of Old and New Treatments for Hematologic Malignancies.
Atkins S, He F. Atkins S, et al. Infect Dis Clin North Am. 2019 Jun;33(2):289-309. doi: 10.1016/j.idc.2019.01.001. Epub 2019 Mar 30. Infect Dis Clin North Am. 2019. PMID: 30935703 Review.
Infection is an important cause of morbidity and mortality in this patient population. Cytotoxic chemotherapy has well-studied infectious risks related to the degree and duration of myelosuppression. ...
Infection is an important cause of morbidity and mortality in this patient population. Cytotoxic chemotherapy has well-studied infect …
Oral chemotherapy for the treatment of hepatocellular carcinoma.
Yamamoto S, Kondo S. Yamamoto S, et al. Expert Opin Pharmacother. 2018 Jun;19(9):993-1001. doi: 10.1080/14656566.2018.1479398. Epub 2018 Jun 18. Expert Opin Pharmacother. 2018. PMID: 29913090 Review.
INTRODUCTION: Many clinical trials have been conducted with chemotherapies in patients with advanced hepatocellular carcinoma (HCC). ...AREAS COVERED: The authors provide an overview of chemotherapies used for the treatment of HCC, including ongoing trials. ...
INTRODUCTION: Many clinical trials have been conducted with chemotherapies in patients with advanced hepatocellular carcinoma (HCC). …
3,534,351 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page